Clinical Trials Browser

Phase 1/2 × Melanoma × mirdametinib × Clear all

NCT00147550 2013-09-13

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Phase 1/2 Terminated

BreastDermatologicGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Melanoma